ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors.

Abstract:

BACKGROUND:Pediatric tumors remain the highest cause of death in developed countries. Research on novel therapeutic strategies with lesser side effects is of utmost importance. In this scenario, the role of Renin-Angiotensin System (RAS) axes, the classical one formed by angiotensinconverting enzyme (ACE), Angiotensin II and AT1 receptor and the alternative axis composed by ACE2, Angiotensin-(1-7) and Mas receptor, have been investigated in cancer. OBJECTIVE:This review aimed to summarize the pathophysiological role of RAS in cancer, evidence for anti-tumor effects of ACE2/Angiotensin-(1-7)/Mas receptor axis and future therapeutic perspectives for pediatric cancer. METHODS:Pubmed, Scopus and Scielo were searched in regard to RAS molecules in human cancer and pediatric patients. The search terms were "RAS", "ACE", "Angiotensin-(1-7)", "ACE2", "Angiotensin II", "AT1 receptor", "Mas receptor", "Pediatric", "Cancer". RESULTS:Experimental studies have shown that Angiotensin-(1-7) inhibits the growth of tumor cells and reduces local inflammation and angiogenesis in several types of cancer. Clinical trials with Angiotensin-( 1-7) or TXA127, a pharmaceutical grade formulation of the naturally occurring peptide, have reported promising findings, but not enough to recommend medical use in human cancer. In regard to pediatric cancer, only three articles that marginally investigated RAS components were found and none of them evaluated molecules of the alternative RAS axis. CONCLUSION:Despite the potential applicability of Angiotensin-(1-7) in pediatric tumors, the role of this molecule was never tested. Further clinical trials are necessary, also including pediatric patients, to confirm safety and efficiency and to define therapeutic targets.

journal_name

Curr Drug Targets

journal_title

Current drug targets

authors

de Paula Gonzaga ALAC,Palmeira VA,Ribeiro TFS,Costa LB,de Sá Rodrigues KE,Simões-E-Silva AC

doi

10.2174/1389450121666200210124217

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

892-901

issue

9

eissn

1389-4501

issn

1873-5592

pii

CDT-EPUB-104354

journal_volume

21

pub_type

杂志文章
  • Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice.

    abstract::It is well documented that elevated levels of PAI-1 in plasma can decrease the fibrinolytic activity in blood with an associated increased risk of thrombus formation. A diverse range of molecules including bacterial lipopolysaccharide (LPS), the inflammatory mediators tumor necrosis factor alpha (TNFalpha) and interle...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007781662382

    authors: Balsara RD,Xu Z,Ploplis VA

    更新日期:2007-09-01 00:00:00

  • Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.

    abstract::Novel anti-vasculature strategies that are emerging for the treatment of cancer and for the inhibition of angiogenesis may be a promising new tool for the adjuvant therapy of malignant tumours. Over the last fifteen years, several reports have been published concerning the relationship between tumour progression and a...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945009789577954

    authors: Pastorino F,Di Paolo D,Loi M,Becherini P,Caffa I,Zorzoli A,Marimpietri D,Carosio R,Perri P,Montaldo PG,Brignole C,Pagnan G,Ribatti D,Allen TM,Ponzoni M

    更新日期:2009-10-01 00:00:00

  • Cell death targeting therapies in B lymphoid malignancies.

    abstract::Programmed cell death, commonly associated with the term apoptosis, is an integrated intracellular program that plays a critical role in lymphoid tissue homeostasis. Alterations in this highly regulated process is a common feature of most lymphoid malignancies, thus facilitating tumor escape from traditional chemother...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945010791320863

    authors: Saborit-Villarroya I,Roué G,López-Guerra M,Alonso R,Xargay-Torrent S,Rosich L,Colomer D

    更新日期:2010-07-01 00:00:00

  • Recent Advances in Computational Methods for Identifying Anticancer Peptides.

    abstract::Anticancer peptide (ACP) is a kind of small peptides that can kill cancer cells without damaging normal cells. In recent years, ACP has been pre-clinically used for cancer treatment. Therefore, accurate identification of ACPs will promote their clinical applications. In contrast to labor-intensive experimental techniq...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450119666180801121548

    authors: Feng P,Wang Z

    更新日期:2019-01-01 00:00:00

  • 5-lipoxygenase: a promising drug target against inflammatory diseases-biochemical and pharmacological regulation.

    abstract::5-Lipoxygenase (5-LO) is the key enzyme involved in the synthesis of pro-inflammatory leukotrienes (LTs) and has become a prime target for new drug discovery research and development efforts by the pharmaceutical and biotech industry. The pathophysiological effects of LTs can be modulated by the selective inhibition o...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450114666131209110745

    authors: Anwar Y,Sabir JS,Qureshi MI,Saini KS

    更新日期:2014-04-01 00:00:00

  • Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels.

    abstract::The growing number of cellular and molecular pathways believed to be involved in mechanisms of ischemic cell death in the brain has spurred a similar growth in the number of potential neuroprotective modalities, the majority of which are pharmacological in nature. Preventing or minimizing the first few steps in the ca...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043345209

    authors: Schurr A

    更新日期:2004-10-01 00:00:00

  • Aldose reductase, still a compelling target for diabetic neuropathy.

    abstract::Aldose reductase (AR) enzymatically transforms cytosolic glucose into sorbitol, a molecule that poorly penetrates cell membranes and is sometimes slowly metabolized. Hyperglycemia can cause intracellular accumulation of sorbitol and its metabolite, fructose, which can create osmotic swelling and cell dysfunction. Driv...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945008783431781

    authors: Oates PJ

    更新日期:2008-01-01 00:00:00

  • Virally encoded G protein-coupled receptors: targets for potentially innovative anti-viral drug development.

    abstract::Various herpes- and poxviruses contain DNA sequences encoding proteins with homology to cellular chemokine receptors, which belong to the family of G protein-coupled receptors (GPCRs). Since GPCRs play a crucial role in cellular communication and chemokine receptors play a prominent role in the immune system, the vira...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450033491000

    authors: Smit MJ,Vink C,Verzijl D,Casarosa P,Bruggeman CA,Leurs R

    更新日期:2003-07-01 00:00:00

  • PDZ Structure and Implication in Selective Drug Design against Cystic Fibrosis.

    abstract::PDZ domains play an essential role in a number of cellular processes by facilitating protein scaffolding and assembly of protein complexes. These domains consist of 80 to 90 amino acids and are found to recognize short C-terminal sequences of target proteins. Protein complex formation between PDZ target molecules can ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666141219120125

    authors: Holcomb J,Spellmon N,Trescott L,Sun F,Li C,Yang Z

    更新日期:2015-01-01 00:00:00

  • Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.

    abstract::Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu(1-8)) receptors, two heterodimeric gamma-aminobutyric acid(B) (GABA(B)) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L-alpha-amino acid receptor (GPRC6A), and five...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007779315614

    authors: Bräuner-Osborne H,Wellendorph P,Jensen AA

    更新日期:2007-01-01 00:00:00

  • The therapeutic value of natural agents to treat miRNA targeted breast cancer in African-American and Caucasian-American women.

    abstract::Breast cancer is the most common cancer in women in the United States, with African-American (AA) women showing significantly higher rates than Caucasian-American (CA) women do. The reason for this racial disparity remains unknown, and factors that might be responsible for the differences in incidence and mortality ha...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945012804545461

    authors: Rahman KM,Sakr WA

    更新日期:2012-12-01 00:00:00

  • Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.

    abstract:BACKGROUND:Osteosarcoma is considered the most frequent primary bone malignancy. Lung metastasis is the leading cause of death and the most consistent factor for predicting negative patient outcome in osteosarcoma. Third-generation nitrogen-containing bisphosphonates, such as zoledronic acid, have been shown to reduce ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1573399811666150615145409

    authors: Ouyang Z,Li H,Zhai Z,Xu J,Dass CR,Qin A,Dai K

    更新日期:2018-01-01 00:00:00

  • Nanocarrier Based Advances in Drug Delivery to Tumor: An Overview.

    abstract:BACKGROUND:Nanotechnology deals with the manufacturing of materials at the atomic and molecular scale. According to the National Nanotechnology Initiative, nanotechnology denotes those structures which are nearly in 1-100 nm size regime in at least one dimension. OBJECTIVE:Nanotechnology in drug delivery has been evid...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450119666180131105822

    authors: Jain A,Kumari R,Tiwari A,Verma A,Tripathi A,Shrivastava A,Jain SK

    更新日期:2018-01-01 00:00:00

  • Thrombomodulin links coagulation to inflammation and immunity.

    abstract::Thrombomodulin (TM) is a type 1 membrane bound glycoprotein that has a C-type lectin domain at its Nterminus, 6 copies of the epidermal growth factor-like (EGF) motif and serine/threonine rich domain carrying a glycosoaminoglycan external to the membrane. TM binds thrombin changing thrombin's substrate specificity fro...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945012799424606

    authors: Morser J

    更新日期:2012-03-01 00:00:00

  • Amendatory Effect of Flavonoids in Alzheimer's Disease Against Mitochondrial Dysfuntion.

    abstract::Flavonoids are chromene analogues abundantly found in plants. It is always of curiosity to discover natural flavonoid structures, since living things, including human, are routinely exposed to these compounds through many dietaries. Indeed, numerous studies conducted so far on flavonoids to display their diverse biolo...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450122666210120144921

    authors: Gulcan HO,Orhan IE

    更新日期:2021-01-20 00:00:00

  • The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems.

    abstract::Oxysterols are pleiotropic messengers interacting with multiple receptor systems. One of the cognate receptors for oxysterols is EBI2, a G protein-coupled receptor highly expressed in the cells of the immune system. Here we discuss the receptor's role in the adapted immunity and inflammation as well as the receptor's ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160217123042

    authors: Rutkowska A,Dev KK,Sailer AW

    更新日期:2016-01-01 00:00:00

  • Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy.

    abstract::The emergency of responsive drug delivery systems has contributed to the reduced cytotoxicity, the improved permeability in tissues and extended circulation time of the active drug. Of particular, enzyme-responsive nanoplatforms have attracted a lot due to the specificity and efficiency of an enzyme-catalyzed reaction...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450122666210114095614

    authors: Lou XF,Du YZ,Xu XL

    更新日期:2021-01-13 00:00:00

  • Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances.

    abstract::Newer classes of medications have been proven useful in glycemic control in type 2 diabetes (T2D), but many do not appear capable to slow down the progressive loss of ß-cell function, or to improve population-level glycemic control. Positive energy balance, e.g. surplus energy intake over expenditure, is at the core f...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450120666181217111500

    authors: Liu Z,Yang B

    更新日期:2019-01-01 00:00:00

  • Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation.

    abstract::Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumi...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111314020008

    authors: Loukides S,Bartziokas K,Vestbo J,Singh D

    更新日期:2013-02-01 00:00:00

  • Targeting heme oxygenase-1 in vascular disease.

    abstract::Heme oxygenase-1 (HO-1) metabolizes heme to generate carbon monoxide (CO), biliverdin, and iron. Biliverdin is subsequently metabolized to bilirubin by biliverdin reductase. HO-1 has recently emerged as a promising therapeutic target in the treatment of vascular disease. Pharmacological induction or gene transfer of H...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111009011504

    authors: Durante W

    更新日期:2010-12-01 00:00:00

  • HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions.

    abstract::Despite the success of combined antiretroviral therapy, more than half of HIV-1-infected patients in the USA show HIV-associated neurological and neuropsychiatric deficits. This is accompanied by anatomical and functional alterations in vulnerable brain regions of the mesocorticolimbic and nigrostriatal systems that r...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150531162212

    authors: Hu XT

    更新日期:2016-01-01 00:00:00

  • Affinity-based methods in drug-target discovery.

    abstract::Target discovery using the molecular approach, as opposed to the more traditional systems approach requires the study of the cellular or biological process underlying a condition or disease. The approaches that are employed by the "bench" scientist may be genetic, genomic or proteomic and each has its rightful place i...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450115666141120110323

    authors: Rylova G,Ozdian T,Varanasi L,Soural M,Hlavac J,Holub D,Dzubak P,Hajduch M

    更新日期:2015-01-01 00:00:00

  • Human Immunodeficiency Virus-1 Cell-To-Cell Transmission And Antiviral Strategies: An Overview.

    abstract::HIV-1 replicates by infecting new target cells either as cell-free viral particle or, much more efficiently, via cell-to-cell viral transmission. Cell-mediated viral spread, in which the infected cell directly transfers the viral particles to target cells via cell-cell contacts, in vitro is up to three orders of magni...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:

    authors: Casartelli N

    更新日期:2015-08-25 00:00:00

  • Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy.

    abstract::Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease a...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666140528151649

    authors: Nascimento AV,Bousbaa H,Ferreira D,Sarmento B

    更新日期:2015-01-01 00:00:00

  • C. elegans: an all in one model for antimicrobial drug discovery.

    abstract::One approach to identify new drugs with antimicrobial activities is to screen large libraries of molecules directly for their capacity to block the growth of bacterial or fungal monocultures. A more relevant way to assess both a product's efficacy and its potential cytotoxicity is undoubtedly to use an in vivo infecti...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011795677854

    authors: Squiban B,Kurz CL

    更新日期:2011-06-01 00:00:00

  • Sphingolipid metabolism enzymes as targets for anticancer therapy.

    abstract::Treatment with anti-cancer agents in most cases ultimately results in apoptotic cell death of the target tumor cells. Unfortunately, tumor cells can develop multidrug resistance, e.g., by a reduced propensity to engage in apoptosis by which they become insensitive to multiple chemotherapeutics. Ceramide. the central m...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043345452

    authors: Kok JW,Sietsma H

    更新日期:2004-05-01 00:00:00

  • Expression and functions of galectin-1 in sensory and motoneurons.

    abstract::Galectin-1 (Gal1) was the first identified member of the galectin family of beta-galactosidase-binding proteins. Gal1 has important roles in processes fundamental to growth and survival of an organism, including cell adhesion, cell proliferation and apoptosis, and is expressed in many tissues, including the nervous sy...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450054021864

    authors: Gaudet AD,Steeves JD,Tetzlaff W,Ramer MS

    更新日期:2005-06-01 00:00:00

  • Natural Products as Anticancer Agents.

    abstract::Medicinal plants and mushrooms have alwaysfascinated the world as an attractive source of natural compounds for cancer therapy. From ancient times, they have been valued as gourmet food and folk medicine in Oriental practice. For over 40 years, world has witnessed the overwhelming interest of western scientific frater...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121999201230204526

    authors: Varghese R,Dalvi YB

    更新日期:2020-12-30 00:00:00

  • Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage.

    abstract:BACKGROUND:Intracranial hemorrhage is characterized by the blood vessel rupture and subsequent hematoma expansion. It is the least treatable stroke subtype, resulting in higher morbidity and mortality per incidence than ischemic stroke. Recent studies have observed lower than normal levels of plasma fibrinogen in patie...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666151209123857

    authors: McBride D,Tang J,Zhang JH

    更新日期:2017-01-01 00:00:00

  • TGF-Beta signaling manipulation as potential therapy for IBD.

    abstract::Crohn's disease (CD) and ulcerative colitis (UC), two chronic and relapsing inflammatory bowel diseases (IBD), are supposed to develop in genetically-predisposed individuals as a result of an excessive immune mucosal response directed against normal components of the gut microbiota. There is also evidence that defects...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/13894501113149990157

    authors: Marafini I,Zorzi F,Codazza S,Pallone F,Monteleone G

    更新日期:2013-11-01 00:00:00